Kristen Maxwell
Family · Demorest, GANPI 1396353355
Payments from drug & device makers
Across 210 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$781
- GSK$400
- Gilead$256
- AstraZeneca$211
- Lilly USA, LLC$187
- Boehringer Ingelheim$185
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,555100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $781 |
| GSK | 29 | $400 |
| Gilead | 12 | $256 |
| AstraZeneca | 12 | $211 |
| Lilly USA, LLC | 13 | $187 |
| Boehringer Ingelheim | 9 | $185 |
| Daiichi Sankyo Inc. | 10 | $175 |
| Corcept Therapeutics | 8 | $168 |
| Xeris Pharmaceuticals, Inc. | 7 | $152 |
| Exact Sciences | 7 | $151 |
| Bayer | 6 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Vanda Pharmaceuticals Inc. | 4 | $84 |
| Alkermes, Inc. | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $43 |
| Novo Nordisk | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Indivior Inc. | 2 | $35 |
| Pfizer | 2 | $35 |
| Vertex | 1 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Medtronic | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Abbott | 1 | $20 |
| Verona Pharma, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Genentech USA, Inc. | 2 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Amgen | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,555 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $121,068 |
| MounjaroTirzepatide | 82 | $97,338 |
| FarxigaDapagliflozin Propanediol | 100 | $95,823 |
| EliquisApixaban | 55 | $68,804 |
| JanuviaSitagliptin Phosphate | 56 | $66,520 |
| JardianceEmpagliflozin | 48 | $54,603 |
| TrulicityDulaglutide | 59 | $51,076 |
| OzempicSemaglutide | 45 | $46,990 |
| ProliaDenosumab | 19 | $33,406 |
| XareltoRivaroxaban | 17 | $20,857 |
| MyrbetriqMirabegron | 21 | $18,147 |
| LinzessLinaclotide | 22 | $17,905 |
| VraylarCariprazine Hcl | 11 | $15,241 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $10,820 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $187 | $148,414141 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $400 | $141,486200 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $211 | $105,796116 claims |
| PfizerEliquis | $35 | $68,80455 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $185 | $65,42376 claims |
| Novo NordiskOzempic | $41 | $46,99045 claims |
| AmgenProlia | $14 | $33,40619 claims |
| AbbVieLinzess, Vraylar | $781 | $33,14633 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $18,14721 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,831237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Demorest
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.